New urine-based test to detect Prostate Cancer could replace painful biopsies

Prostate cancer is no stranger to headlines, being the most common cancer and the second leading cause of cancer death among men in the United States. Traditionally, confirming the diagnosis has meant enduring invasive and often uncomfortable biopsies. But thanks to some brilliant minds at Johns Hopkins, there may soon be a simpler, urine-based alternative that could change the game entirely.

The new test zeroes in on three key biomarkers in urine: TTC3, H4C5, and EPCAM. Researchers analyzed samples from prostate cancer patients before and after prostate-removal surgery and found these markers almost vanished post-surgery. That confirmed their origin in prostate tissue, making them reliable signposts for detecting the disease. In validation studies, the test accurately identified prostate cancer 91 percent of the time and correctly ruled out those without the disease 84 percent of the time. That is a serious upgrade over the traditional PSA test, which often leaves men undergoing unnecessary biopsies or treatments.

Why does this matter? PSA tests are not very specific and can produce false alarms, leading to biopsies that may come back negative and sometimes even cause complications. This urine-based test offers a noninvasive, stress-free alternative that could spare patients discomfort while still catching the disease early when treatment works best. Impressively, it even detects prostate cancer in men with normal PSA levels and can differentiate between cancer and other conditions like prostatitis or an enlarged prostate.

Doctors are thrilled. With a simple urine sample, clinicians could soon improve diagnostic accuracy, reduce unnecessary interventions, and start treatment early for those who truly need it. It is a small sample with a big impact, potentially redefining how we detect prostate cancer in the modern age.
**This news was published on Times of India on 3rd September, 2025.

 

 

 

Source Click